Pfizer Seeks Better Definition Of FDA Limits On Ad Similarity, Proximity
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer is asking FDA to clarify how different and how distant help-seeking ads must be from direct-to-consumer full product ads to comply with the agency's disease awareness draft guidance
You may also be interested in...
FDA Should Allow Linkages Between "Help-Seeking" and Full Product Ads, Pfizer Says
Similarities between disease awareness ads and full product ads, which contain risk information, could benefit consumers, Pfizer says in comments on FDA's draft DTC guidance. The company is working with consumer and medical groups to generate such evidence.
FDA Should Allow Linkages Between "Help-Seeking" and Full Product Ads, Pfizer Says
Similarities between disease awareness ads and full product ads, which contain risk information, could benefit consumers, Pfizer says in comments on FDA's draft DTC guidance. The company is working with consumer and medical groups to generate such evidence.
Disease Awareness Ads Must Be Different, Distant From Branded Ads, FDA Says
FDA is encouraging the use of disease awareness advertisements but warns that ads too similar or shown too close together with branded spots could result in product withdrawal.